1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Veracyte, Inc.
  6. Summary
    VCYT   US92337F1075

VERACYTE, INC.

(VCYT)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
23.93 USD   +2.22%
06/27Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
BU
06/20New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practice
BU
06/20Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
19.97(c) 19.9(c) 21.1(c) 23.41(c) 23.93(c) Last
887 180 816 627 795 021 1 200 151 1 176 725 Volume
+0.71% -0.35% +6.03% +10.95% +2.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 272 M - -
Net income 2022 -55,5 M - -
Net cash position 2022 163 M - -
P/E ratio 2022 -29,9x
Yield 2022 -
Sales 2023 324 M - -
Net income 2023 -42,6 M - -
Net cash position 2023 183 M - -
P/E ratio 2023 -39,0x
Yield 2023 -
Capitalization 1 710 M 1 710 M -
EV / Sales 2022 5,68x
EV / Sales 2023 4,71x
Nbr of Employees 761
Free-Float 99,1%
More Financials
Company
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy... 
More about the company
Ratings of Veracyte, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about VERACYTE, INC.
06/27Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecuti..
BU
06/20New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practi..
BU
06/20Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Cli..
CI
06/16VERACYTE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/13TRANSCRIPT : Veracyte, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Confer..
CI
06/13INSIDER BUY : Veracyte
MT
06/03Veracyte Says Study Data Show Utility of Prostate Genomic Classifier
MT
06/03Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher ..
BU
06/03Veracyte, Inc. Announces the Publication of Data Reinforcing the Clinical Utility of th..
CI
05/31Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely ..
BU
05/31Veracyte, Inc. Announces that New Data Show Immunoscore IC Assay May Predict Patients L..
CI
05/26 New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Ge..
BU
05/26Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's..
BU
05/26Veracyte, Inc. Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC A..
CI
05/26Veracyte to Present at Upcoming Investor Conferences
BU
More news
News in other languages on VERACYTE, INC.
06/20Veracyte, Inc. montre la forte performance de l'Afirma GSC de Veracyte dans la pratique..
06/13ACHAT D'INITIÉS : Veracyte
06/03Veracyte affirme que les données de l'étude montrent l'utilité du classificateur génomi..
06/03Veracyte, Inc. annonce la publication de données renforçant l'utilité clinique du class..
05/31Veracyte, Inc. annonce que de nouvelles données montrent que le test Immunoscore IC peu..
More news
Analyst Recommendations on VERACYTE, INC.
More recommendations
Chart VERACYTE, INC.
Duration : Period :
Veracyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERACYTE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 23,93 $
Average target price 30,67 $
Spread / Average Target 28,2%
EPS Revisions
Managers and Directors
Marc A. Stapley Chief Executive Officer & Director
Rebecca Chambers Chief Financial Officer
Bonnie H. Anderson Executive Chairman
Richard T. Kloos Executive Medical Director
Giulia C. Kennedy Global Chief Scientific & Medical Officer
Sector and Competitors